Suzhou News Reports on RocRock Biotechnology: Innovation Leads, Building a Healthy Future Together

On August 5, 2024, a team of reporters from Suzhou Broadcasting visited RocRock Biotechnology, located in the BioBAY industrial park, and conducted an in-depth interview with the company's founder, Dr. Yin Xiushan. During the interview, the reporters also toured the laboratories of RocRock Biotechnology. The interview content was aired as the headline in the Suzhou News program, showcasing the scientific research capabilities, spirit of innovation, and results of international cooperation of RocRock Biotechnology.

(Suzhou News video)

RocRock Biotechnology's core team established a profound cooperative relationship with Armenia at the beginning of the pandemic outbreak, helping Armenia to build a testing reagent production and technology platform through collaborative efforts. From July 7th to July 10th, 2024, Dr. Yin Xiushan led a delegation from RocRock Biotechnology and Shandong First Medical University to visit Armenia, a country along the Belt and Road Initiative, to focus on the prevention and treatment of Mediterranean fever, a rare disease, and reached a cooperation intention on a national-level rare disease project between China and Armenia.

The highest scientific research institution in Armenia, the Armenian National Science Academy, awarded Dr. Yin Xiushan with the National Gold Medal in recognition of his significant contributions to Armenia's health sector during the COVID-19 pandemic.

Based on the successful development of test kits and the accumulation of experience, RocRock Biotechnology has cooperated with Shandong First Medical University to establish joint laboratories in Armenia and China. Breakthrough progress has been made in the drug development for Mediterranean fever, with clinical trials expected to start in the second half of this year. This cooperation represents a pioneering global attempt at treating rare diseases with technology rather than drugs, aiming to solve the heavy financial burden of expensive medical costs for rare disease patients and the country, truly achieving the accessibility of rare disease treatments.

RocRock Biotechnology focuses on the development and clinical application of macrophage drug treatments for solid tumors. Since its establishment, the company has actively promoted the research and development and industrialization of chimeric antigen receptor macrophage (CAR-M) high-tech. Currently, it is collaborating with multiple global institutions on multi-center cooperation to advance 8 CAR-M cell drug pipelines, targeting HER2-positive solid tumors, pancreatic cancer, lung cancer, liver cancer, glioma, systemic lupus erythematosus, and pulmonary fibrosis. RocRock Biotechnology is committed to achieving the successful launch of 2 innovative drugs within 5-6 years, placing our country at the forefront of macrophage therapy for solid tumors globally and becoming a leader in CAR-M, tirelessly working towards extending the lifespan of every solid tumor patient by 24 years. In the future, RocRock Biotechnology will adhere to its open and innovative DNA, follow the guiding principles of high-quality development of the "Belt and Road" initiative proposed by the third plenary session, and aim for technology export and profit. It will also collaborate with European and American countries to further expand product technology and pipelines, promote more innovative therapies into clinical application, and benefit patients.